Best Life Sciences Platforms and Tools Companies in Seoul, South Korea
The 72 best Life Sciences Platforms and Tools companies in Seoul, South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cellid.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Seoul
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Cellid Developer of personalized vaccines to treat cancer and infectious diseases 32Patents top 32%Funding top 35%Innovation top 40%Moat top 45% All 8 signals ▾Patentstop 32% Fundingtop 35% Innovationtop 40% Moattop 45% Marketbottom 48% Globalbottom 35% Fin. healthbottom 35% Techbottom 22% Patents: 32 patents matched (strict assignee match) · 26 filings since 2022 vs 4 in 2017-21 Funding: Raised $2.4B across 1 rounds · 1 rounds over 12 yrs (0.1/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $2.4B | 120 mo ago | Public | — | 2014 | PHPNginxNaver Analytics+5 | 32 patents NK cell-based cancer vaccines and replication-deficient adenoviral vector platforms | — |
| 2 | ROKIT Healthcare Provider of 4D bio-printer solutions for tissue regenerative 64Patents top 24%Innovation top 26%Tech top 28%Product top 28% All 11 signals ▾Patentstop 24% Innovationtop 26% Techtop 28% Producttop 28% Moattop 29% Fundingtop 33% Growthtop 35% Markettop 50% Talentbottom 49% Fin. healthbottom 43% Globalbottom 42% Patents: 168 patents matched (strict assignee match) · 84 filings since 2022 vs 84 in 2017-21 Innovation: 168 patents (top 10% of patent-holders) · 84 filings since 2022 vs 84 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $30M | 3 mo ago | Public | Seokhwan You Chairman & Ceo | 2012 | Cart FunctionalityWordPressMySQL+25 | 168 patents Patents concentrated in health & consumer products | — |
| 3 | Curiox Developer of wall-less plates and washers for automated cell-based assays | $30M | 51 mo ago | Public | Leck Joo Co-Founder | 2007 | WordPressBetterDocsMySQL+41 | — | 1 launch · 1 award |
| 4 | Mepsgen Developer of human organ model chips for pharmaceutical development 42Patents top 24%Moat top 32%Funding top 34%Innovation top 35% All 9 signals ▾Patentstop 24% Moattop 32% Fundingtop 34% Innovationtop 35% Growthtop 35% Talentbottom 49% Globalbottom 43% Marketbottom 33% Techbottom 24% Patents: 49 patents matched (strict assignee match) · 47 filings since 2022 vs 2 in 2017-21 Moat: Editorial + unicorn rating 4/10 · IP moat: 49 patents rank vs industry peers · Fliar Intelligence Index 42/100 | $29M | 19 mo ago | Series C | Yongtae Kim Co-Founder & CEO | 2019 | DreamWeaverPHPYouTube+10 | 49 patents Microfluidic production of uniform lipid/HDL nanoparticles for drug delivery | — |
| 5 | Lemonex Developer of drug delivery technology and biosensor technology | $27M | 62 mo ago | Series C | Dal-Hee Min Co-Founder & CTO | 2013 | — | 181 patents Nanocarrier-based drug and nucleic‑acid delivery systems for antiviral and cancer therapies | — |
| 6 | NEXEL Provider of induced pluripotent stem cell (iPSC)-derived cells and organoids | $27M | 62 mo ago | Series B | Choongseong Han CEO | 2012 | PHPBootstrapNginx+10 | 68 patents Patents concentrated in health & consumer products | — |
| 7 | Genacast Provider of liquid-biopsy-based cancer detection platform | $12M | 72 mo ago | Series B | Seung Chan Baek CEO | 2016 | — | — | — |
| 8 | NanoEntek Develops point-of-care instruments for in vitro diagnostics and life science research. | $8M | 130 mo ago | Public | — | 2000 | GnuboardMySQLPHP+19 | 152 patents Microfluidic particle and cell counting chips for precise fluid analysis | — |
| 9 | ENCell Provider of services for stem cell research for drug development | $8M | 75 mo ago | Series A | Jang wook CEO | 2018 | Microsoft ASP.NETCloudflarejsDelivr+8 | 70 patents Patents concentrated in chemistry & materials | — |
| 10 | Cellivery Peptide drug delivery platform | $6M | 109 mo ago | Public | — | 2014 | PHPNginxSlick+7 | — | — |
| 11 | The Wave Talk Developer of biosensors to detect and monitor micro-organisms | $2M | 74 mo ago | Seed | Youngdug Kim Co-Founder & CEO | 2016 | Wix eCommerceWixSentry+12 | 148 patents Optical and wave‑based sensors for turbidity and fluid property measurement | 1 launch |
| 12 | Seegene Technologies Developer of molecular diagnostic kits to detect infectious and genetic diseases | $2M | 78 mo ago | Public | Jong Yoon Chun CEO | 2000 | Node.jsSalesforceTailwind CSS+14 | 1,257 patents Multiplex nucleic‑acid diagnostic assay design, automation, and data‑driven infectious disease testing | 1 launch · 1 award |
| 13 | Anymedi Provider of platform for medical image upload, 3D modeling, and 3D printing service | $1M | 103 mo ago | Seed | Guk Bae Kim CEO | 2016 | — | 51 patents Neurosurgical navigation guides, personalized surgical guides, and endoscopic simulation training devices. | — |
Top 12 Life Sciences Platforms and Tools companies in Seoul
#1
Public · Seoul, Seoul · founded 2012 · 65 employees$30Mraised▾
ROKIT HEALTHCARE provides 4D bio-printer solutions for tissue regenerative. The company offers its propriety technology for organ regeneration and 3D bio-fabrication technologies for personalized therapy in the areas of skin, cartilage, retina and heart patch regeneration. The company flagship product INVIVO, is a sterilized printer equipped for developing the biomolecules, and polymers to create 3D structures.
- Mar 2026Post IPO$42.1M
- Jul 2020Series C—
- Jan 2019Series B$9.9M
- 2015Grant (prize money)$3M
#2
Series C · Seoul, Seoul · founded 2019 · 20 employees$29.3Mraised▾
Developer of human organ model chips for pharmaceutical development. The company develops and produces a 3D cell cultures organ-on-a-chip platform such as the MEPS-X series and MG-X series to develop drug candidates which target Alzheimer's and brain tumors.
- Nov 2024Series C$14.8M
- Jul 2022Series B$8M
- Aug 2021Series A$3.5M
- Aug 2020Series A$2.9M
#3
Public · Seoul, Seoul · founded 2014 · 68 employees$2.4Braised▾
Cellid is involved in developing personalized vaccines for treating cancer and infectious diseases. They have developed a platform, CeliVax, which activates the anti-cancer immune system which allows the immune cells to detect and kill cancer cells. Their pipeline products include BVAC-C is being investigated for cervical, head, and neck cancer, and BVAC-B for gastric cancer. The candidates are in phase II clinical trial.
- 2016Series A—
- 2015Series A—
- 2014Series A—
- 2014Series A—
#4
Public · Seoul, Seoul · founded 2007 · 57 employees$30Mraised▾
Curiox is a bioinstrumentation company spun out of the Agency for Science, Technology, and Research (A*STAR) in Singapore. The company has designed wall-less plates and washers to automate miniaturized cell-based assays. This novel DropArray technology can be miniaturized down to 5ul with minimal changes to the customer workflow. Its products include DropArray Microplate, HT200 Washing Station, and LT210 Washing Station.
- Mar 2022Series C$15M
- Oct 2019Series B$15M
- Oct 2009Series B—
- Dec 2007Series A—
#5
Series C · Seoul, Seoul · founded 2013 · 9 employees$27.5Mraised▾
Developer of drug delivery technology and biosensor technology. The DegradaBALLis a drug delivery technology for the development of gene therapy, cancer immunotherapy, antibody therapy, and synthetic drugs. The PANGO technology is the next-generation drug screening technology that allows the rapid screening of antiviral drugs from the drug candidate library.
- Apr 2021Series C$13.9M
- Dec 2018Series B$10.3M
- Mar 2018Series A$3.3M
#6
Series B · Seoul, Seoul · founded 2012 · 22 employees$27Mraised▾
Provider of induced pluripotent stem cell (iPSC)-derived cells and organoids. It manufactures iPSC-derived cardiomyocytes, neurons, and hepatocytes for drug response, 3D printing, and electrophysiological experiments. The company also produces iPSC-derived cardiac and heart organoids, offering services in cardiac safety evaluation, custom cell production, and iPSC reprogramming. It develops and patents new drug candidates using hiPSC-based technologies and disease models. These services support drug development, reducing reliance on animal testing.
- Apr 2021Series B$15.6M
- 2019Series B—
#7
Series B · Seoul, Seoul · founded 2016 · 27 employees$11.6Mraised▾
“The earlier you discover, the better you recover†GENECAST is biotechnology company specialized in cancer diagnosis using liquid biopsy. ADPS, our proprietary technology which has maximum detection sensitivity of 0.0001%, can recognize cancer mutation genes quickly and accurately among other conventional liquid biopsy technologies. FACE CANCER with ADPS
#8
Series A · Seoul, Seoul · founded 2018 · 104 employees$8Mraised▾
Provider of services for stem cell research for drug development. The company is developing next-generation cell/gene therapy and targeted gene therapy for incurable and incurable diseases. Also, offers CMO and CDMO services for drug development.
- Mar 2020Series A$8M
- Seed—
#9
Public · Seoul, Seoul · founded 2000 · 138 employees$8.4Mraised▾
NanoEntek develops point-of-care instruments for in vitro diagnostics and life science research. Its flagship products use proprietary MEMS fabrication technologies. NanoEntek has solutions FREND and BUDDI for automated immunoassays, ADAM for rWBC counting, and the JULI series for cell counting. In addition, the company also provides associated reagents and kits for various disease areas, including oncology and infectious diseases.
- Aug 2015Post IPO$8.4M
#10
Public · Seoul, Seoul · founded 2014 · 100 employees$6.3Mraised▾
Cellivery is a protein-based drug discovery/development company commercializing its platform technology for effective delivery of therapeutic macromolecules to the intracellular space. The company's platform exploits the ability of specific basic-, amphipathic- and hydrophobic- cell penetrating peptide (CPP) sequences to enhance the uptake of proteins and other macromolecules by mammalian cells. The company is developing its proprietary CPPs (aMTD, or Advanced Macromolecule Transduction Domains) linked to therapeutic peptides and proteins as biologic therapeutics to create novel drugs against cancer and other diseases. The company is currently in preclinical stage for 12 candidates for multiple cancers.
- May 2017Series A$6.3M
#11
Seed · Seoul, Seoul · founded 2016 · 14 employees$2Mraised▾
Developer of biosensors to detect and monitor micro-organisms. The technology detects the activity of microorganism within the human body through machine learning to provide personal health information. The company provide services for the food and healthcare industries.
- Apr 2020Seed$2M
- 2018Seed—
- Jul 2017Seed—
#12
Public · Seoul, Seoul · founded 2000$1.6Mraised▾
Developer of molecular diagnostic kits to detect infectious and genetic diseases. It has developed IVD tests that detect causes of disease by analyzing nucleic acids such as DNA and RNA which contain genetic information. It has IVD reagents including kits for detecting respiratory diseases, gastrointestinal diseases, sexually transmitted diseases (STDs), human papillomavirus (HPV), tuberculosis, sepsis, and meningitis.
- Dec 2019Grant (prize money)$1.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Seoul is moving
A read on the academic research around Bioinformatics in Seoul — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 188 papers.
- Seoul National University134
- Seoul National University Hospital37
- Seoul National University Bundang Hospital13
- The Catholic University of Korea Seoul St. Mary\'s Hospital8
- Hanyang University Seoul Hospital7
- Gene1→7
- Protein structure prediction1→3
- Genome4→5
- Microbiome6
- Disease6
- Immune system5
- Gene4
- Pathogenesis3
- Table (database)12
- Transcriptome12
- Sample (material)12
- Clinical trial3
- Immunotherapy3
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.